Fundraising Fox
Locus Biosciences
Raleigh, US · Founded 2015 · Delaware corporation · 57 employees on LinkedIn · 9 known investors
Find your way into Locus Biosciences
Each arrow is one introduction. Sign up to fill in the first one.
Ask Austin Walne to introduce you to Nick Conley
You →Austin · together at Locus Biosciences →Nick
Ask Jamie Chen to introduce you to NICK TAYLOR
You →Jamie · together at Locus Biosciences →NICK
Sign up to find every way you can get introduced to Locus Biosciences
- Your email: who you already know at Locus Biosciences, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Locus Biosciences team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Locus Biosciences develops engineered bacteriophage therapies for treating bacterial infections and conditions in immunology, oncology, and CNS disorders. It uses a technology platform combining robotics, automated biobanking, AI-driven cocktail prediction, and synthetic biology, and operates a cGMP viral vector manufacturing facility for clinical trial material.
Founders & leadership
Locus Biosciences was founded in 2015 by Paul Garofolo.
Board
Investors · 9
How we know: Artis Ventures's portfolio page · the company's own site · funding news · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Abstract Ventures's portfolio page · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Hemisphere Ventures LLC's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: press coverage · Not right? Tell us
Also in the syndicate · 2
Funding
SEC filings, press & company announcements$46.3M disclosed across 6 of 7 rounds · 2016–2024
- Undisclosed amountSeries CFeb 2024
Johnson & Johnson (lead), Braeburn Capital, Domain Associates, Longitude Capital
Source ↗
▶$10.6MraisedFeb 2022 · 3 investors · BiotechnologyRule 506(b)
- Bary BaileyDirector
- David OusteroutExecutive Officer
- Joseph NixonExecutive Officer
- Stuart PetersonDirector
- Paul GarofoloExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $10.6M
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$20MraisedNov 2020 · 34 investors · BiotechnologyRule 506(b)
- STUART PETERSONDirector
- BARY BAILEYDirector
- PAUL GAROFOLOExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7MraisedJul 2018 · 24 investors · BiotechnologyRule 506(b)
- STUART PETERSONDirector
- BARY BAILEYDirector
- PAUL GAROFOLOExecutive Officer, Director
- Offering amount
- $7M
- Amount sold
- $7M
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$7MraisedOct 2017 · 2 investors · BiotechnologyRule 506(b)
- PAUL GAROFOLOExecutive Officer, Director
- BARY BAILEYDirector
- STUART PETERSONDirector
- Offering amount
- $14M
- Amount sold
- $7M
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$350KraisedDec 2016 · 1 investors · BiotechnologyRule 506(b)
- BARY BAILEYDirector
- GEOFFREY GLASSDirector
- NICK TAYLORExecutive Officer
- CHUCK BRAMLAGEDirector
- PAUL GAROFOLOExecutive Officer, Director
- DAVID JOHNSTONDirector
- Offering amount
- $7M
- Amount sold
- $350K
- First sale
- Dec 2016
- Incorporated
- Corporation, North Carolina, 2015
- Federal exemptions
- 06b
▶$1.3MraisedApr 2016 · 62 investors · BiotechnologyRule 506(b)
- GEOFFREY GLASSDirector
- DAVID JOHNSTONDirector
- NICK TAYLORExecutive Officer
- PAUL GAROFOLOExecutive Officer, Director
- BARY BAILEYDirector
- CHUCK BRAMLAGEDirector
- Offering amount
- $1.5M
- Amount sold
- $1.3M
- First sale
- Jan 2016
- Incorporated
- Corporation, North Carolina, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
5 people who came through Locus Biosciences went on to found or lead other companies.
Related companies · 2
Companies working in the same space as Locus Biosciences.
In the news
Frequently asked questions
- What does Locus Biosciences do?
- Locus Biosciences develops engineered bacteriophage therapies for treating bacterial infections and conditions in immunology, oncology, and CNS disorders. It uses a technology platform combining robotics, automated biobanking, AI-driven cocktail prediction, and synthetic biology, and operates a cGMP viral vector manufacturing facility for clinical trial material.
- Who founded Locus Biosciences?
- Locus Biosciences was founded by Paul Garofolo in 2015.
- Who are Locus Biosciences's investors?
- Locus Biosciences's investors include Artis Ventures, Abstract Ventures, Hemisphere Ventures LLC, Domain Associates, Longitude Capital, Starlight Ventures, Tencent Holdings.
- How much funding has Locus Biosciences raised?
- Locus Biosciences has disclosed $46.3M raised across 6 of its 7 known rounds.
- Where is Locus Biosciences headquartered?
- Locus Biosciences is headquartered in Raleigh, US.